Plasma Expression Levels of Circulating miR-21 are not Useful for Diagnosing and Monitoring Colorectal Cancer

被引：13

作者：

Montagnana, Martina ^{[1
]}

Benati, Marco ^{[1
]}

Danese, Elisa ^{[1
]}

Minicozzi, Anna Maria ^{[2
]}

Paviati, Elisa ^{[1
]}

Gusella, Milena ^{[3
]}

Pasini, Felice ^{[3
]}

Bovo, Chiara ^{[4
]}

Guidi, Gian Cesare ^{[1
]}

Lippi, Giuseppe ^{[1
]}

机构：

[1] Univ Verona, Clin Biochem Sect, Dept Neurosci Biomed & Movement Sci, I-37100 Verona, Italy

[2] Royal London Hosp, London E1 1BB, England

[3] Osped S Maria Misericordia, Dept Oncol, ULSS Rovigo 18, Rovigo, Italy

[4] Univ Hosp Verona, Med Direct, Verona, Italy

来源：

CLINICAL LABORATORY | 2016年 / 62卷 / 05期

关键词：

DIFFERENTIAL EXPRESSION; COLON; MICRORNA-21; PROGNOSIS; PDCD4; GENE;

D O I：

10.7754/Clin.Lab.2015.151015

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background: Recent evidence suggests that microRNAs play an important role in cancer diagnostics. We assessed plasma microRNA-21 levels in patients with colorectal cancer (CRC) at different stages and in patients with benign polyps. Methods: Plasma levels of miR-21 were assessed by quantitative reverse transcription polymerase chain reaction assay in plasma samples of 76 CRC patients and in 20 patients with benign polyps. Differences between groups were evaluated with Mann-Whitney and Kruskal-Wallis tests. Results: No significant differences of miR-21 plasma levels were observed between CRC patients and subjects with benign polyps (p > 0.05). Also, no significant differences were found between CRC patients with advanced (III-IV) or early cancer stages (I-II) (p > 0.05). Conclusions: These results do not support the hypothesis that circulating miR-21 expression is increased in adenoma-carcinoma-advanced carcinoma sequence. Accordingly, plasma miR-21 assessment does not appear to be a useful biomarker for diagnosing and staging CRC.

引用

页码：967 / 970

页数：4

共 21 条

[1] MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer [J].